The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Open accessAbstract
Abstract Purpose: Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degradation of tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveillance. This first-in-human phase I study investigated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of epacadostat (INCB024360), a potent and selective inhibitor of IDO1. Experimental Design: Fifty-two patients with advanced solid malignancies were treated with epacadostat [50 mg once daily or 50, 100, 300, 400, 500, 600, or 700 mg twice daily (BID)] in a dose-escalation 3 + 3 design and evaluated in 28-day cycles. Treatment was continued until disease progression or unacceptable toxicity. Results: One dose-limiting toxicity (DLT) occurred at the dose of 300 mg BID (grade 3, radiation pneumonitis); another DLT occurred at 400 mg BID (grade 3, fatigue). The most common adverse events in >20% of patients overall were fatigue, nausea, decreased appetite, vomiting, constipation, abdominal pain, diarrhea, dyspnea, back pain, and cough. Treatment produced significant dose-dependent reductions in plasma kynurenine levels and in the plasma kynurenine/tryptophan ratio at all doses and in all patients. Near maximal changes were observed at doses of ≥100 mg BID with >80% to 90% inhibition of IDO1 achieved throughout the dosing period. Although no objective responses were detected, stable disease lasting ≥16 weeks was observed in 7 of 52 patients. Conclusions: Epacadostat was generally well tolerated, effectively normalized kynurenine levels, and produced maximal inhibition of IDO1 activity at doses of ≥100 mg BID. Studies investigating epacadostat in combination with other immunomodulatory drugs are ongoing. Clin Cancer Res; 23(13); 3269–76. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regarding dosing of epacadostat, 100 mg was taken forward out of the phase I study despite higher dose levels being tolerable and no maximum tolerated dose being established (59).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Self-citationPrevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Research works printed but not linked: 1
- Gangadhar, 2016, Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037, Ann Oncol, 27, vi381, 10.1093/annonc/mdw379.06 · DOI
Cited by
Sorted by citations
Items 201–300 of 324
Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy
Bautista, J., Echeverría, C. E., Maldonado-Noboa, I., Adatty-Molina, J., Urresta, S. S., Coral-Riofrio, E. C., Araujo‐Abad, S., Kyriakidis, N. C., & López-Cortés, A. (2026) · Journal of Immunology Research · doi:10.1155/jimr/7864229 · Cited by 16
Öztürk, S., Kalter, V., Roessner, P. M., Sünbül, M., & Seiffert, M. (2021) · Cancers · doi:10.3390/cancers13081899 · Cited by 14
Ye, K., Wang, K., Wang, T., Tang, H., Wang, L., Zhang, W., Jiang, S., Zhang, X., & Zhang, K. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115217 · Cited by 13
Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials
Salawu, A., Hernando‐Calvo, A., Chen, R. Y., Araújo, D. V., Oliva, M., Liu, Z. A., & Siu, L. L. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.045 · Cited by 19
Zheng, R., Huang, C., Zhou, H., Zhao, L., Li, Q., Chen, G., Zhao, L., & Li, S. (2024) · Aggregate · doi:10.1002/agt2.610 · Cited by 13
Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma
Liang, C., Peng, L., Zeng, S., Zhao, Q., Tang, L., Jiang, X., Zhang, J., Yan, N., & Chen, Y. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.01.005 · Cited by 13
PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang, R., Zhang, Y., & Shan, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108484 · Cited by 13
Boyer, M. J., Hui, R., Urban, D., Clingan, P. R., Su, W., Devaux, C., Gadgeel, S. M., Garassino, M. C., Leopold, L. H., Daniel, J., et al. (2024) · BMC Cancer · doi:10.1186/s12885-022-10427-4 · Cited by 14
Self-citationZheng, Y. J., Stafford, P. M., Stover, K. R., Mohan, D. C., Gupta, M., Keske, E. C., Schiavini, P., Villar, L., Wu, F., Kreft, A., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100107 · Cited by 12
de Iudicibus, R. C., Tomek, P., Palmer, B. D., Tijono, S., Flanagan, J. U., & Ching, L. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116160 · Cited by 12
Aryl Hydrocarbon Receptor as an Anticancer Target: An Overview of Ten Years Odyssey
Hanieh, H., Ismail, M. B., Alfwuaires, M. A., Ibrahim, H.-I. M., & Farhan, M. (2023) · Molecules · doi:10.3390/molecules28103978 · Cited by 14
Insights into immuno-oncology drug development landscape with focus on bone metastasis
Kähkönen, T. E., Halleen, J. M., MacRitchie, G., Andersson, R. M., & Bernoulli, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121878 · Cited by 12
Xu, P., Sun, C., Cao, X., Zhao, X., Dai, H., Lu, S., Guo, J., Fu, S., Liu, Y., Li, S.-C., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.06.010 · Cited by 13
Kiyozumi, Y., Baba, Y., Okadome, K., Yagi, T., Ogata, Y., Eto, K., Hiyoshi, Y., Ishimoto, T., Iwatsuki, M., Iwagami, S., et al. (2019) · Cancer Science · doi:10.1111/cas.14028 · Cited by 12
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1
Jiang, S., Li, H., Piao, L., Jin, Z. G., Liu, J., Chen, S., Liu, L. L., Shao, Y., Zhong, S., Wu, B., et al. (2020) · Aging · doi:10.18632/aging.103113 · Cited by 12
Cai, Z., Tu, L., Tian, S., Deng, L., Fu, Y., Phan, C., van den Bosch, T. P. P., Tran‐Lundmark, K., Nagy, B. M., Olschewski, H., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040896 · Cited by 12
Tahaghoghi-Hajghorbani, S., Yazdani, M., Nikpoor, A. R., Hatamipour, M., Ajami, A., Jaafari, M. R., Badiee, A., & Rafiei, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-31007-x · Cited by 11
Li, Y., Chen, K., Chen, B., Zeng, R., He, Y., Wang, C., Zhong, M., Liu, X., Chen, X., Xiao, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02266-y · Cited by 11
Nanomedicines modulate the tumor immune microenvironment for cancer therapy
Chao, P., Chan, V., & Li, S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2412245 · Cited by 13
Emerging Immunotherapy Targets in Early Drug Development
Araujo, D. M., Catani, G., Mirallas, O., Pretelli, G., Sánchez-Pérez, V., Vieito, M., Braña, I., Pujol‐Borrell, R., Garralda, E., & Hernando‐Calvo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115394 · Cited by 12
Dual‐Targeting Nanoliposome Improves Proinflammatory Immunomodulation of the Tumor Microenvironment
Gu, Z., Silva, C. G. D., Ma, S., Liu, Q., Schomann, T., OSSENDORP, F. A., & Cruz, L. J. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302046 · Cited by 11
Rocco, D., Gregorc, V., Gravara, L. D., Lazzari, C., Palazzolo, G., & Gridelli, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1793956 · Cited by 11
Doi, T., Fujiwara, Y., Shitara, K., Shimizu, T., Yonemori, K., Matsubara, N., Ohno, I., Kogawa, T., Naito, Y., Leopold, L. H., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00942-1 · Cited by 11
Self-citationFujiwara, Y., Kato, S., Nishizaki, D., Miyashita, H., Lee, S., Nesline, M., Conroy, J. M., DePietro, P., Pabla, S., Lippman, S. M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109632 · Cited by 11
Khoshkhabar, R., Yazdani, M., Alavizadeh, S. H., Saberi, Z., Arabi, L., & Jaafari, M. R. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112437 · Cited by 10
Maletzki, C., Scheinpflug, P., Witt, A., Klar, E., & Linnebacher, M. (2019) · BioMed Research International · doi:10.1155/2019/4938285 · Cited by 10
Zhang, S., Wang, S., Wang, Y., Zhou, T., Yang, J., Xu, J., Li, G., Zhang, Y., Wang, X., & Yin, H. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4162 · Cited by 11
Klar, R., Michel, S., Schell, M., Hinterwimmer, L., Zippelius, A., & Jaschinski, F. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02438-1 · Cited by 9
Wang, Y., Zhang, L., Bai, Y., Wang, L., & Ma, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1036298 · Cited by 9
Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
Isaacs, J., Tan, A. C., Hanks, B. A., Wang, X., Owzar, K., Herndon, J. E., Antonia, S. J., Piantadosi, S., & Khasraw, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1593 · Cited by 9
Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer
Powles, T. B., & Rini, B. I. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2655 · Cited by 9
Guo, H., Liu, C., Wu, K., Li, Y., Zhang, Z., & Chen, F. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04015-1 · Cited by 8
Structural Insights into Protein-Inhibitor Interactions in Human Tryptophan Dioxygenase
Geeraerts, Z., Ishigami, I., Lewis-Ballester, A., Pham, K., Kozlova, A., Mathieu, C., Frédérick, R., & Yeh, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01360 · Cited by 8
Souissi, S., Ghedira, R., Macherki, Y., Ben‐Haj‐Ayed, A., Gabbouj, S., Remadi, Y., Sfar, I., Chadli, Z., Aouam, K., Hassine, M., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.690 · Cited by 8
Aboomar, N. M., Essam, O., Hassan, A., Bassiouny, A. R., & Arafa, R. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-59353-4 · Cited by 7
Giglio, B., Wang, H., Yan, X., & Li, Z. (2019) · MedChemComm · doi:10.1039/c9md00082h · Cited by 7
The exploitation of enzyme-based cancer immunotherapy
Chandan, G., Saini, A. K., Kumari, R., Chakrabarti, S., Mittal, A., Sharma, A. K., & Saini, R. V. (2022) · Human Cell · doi:10.1007/s13577-022-00821-2 · Cited by 7
Li, X., Meng, H., Wang, H., Zhang, Y., & Yu, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1640073 · Cited by 10
li, Y., Zhang, Y., Nie, Y., & Chen, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1678446 · Cited by 8
Heydari, F., Zendehdel, H., Varkiani, M. M., Fahmi, S., Derakhshani, M., Anvari, S., Farhid, F., Hamblin, M. R., & Naghinezhad, J. (2026) · Biomarker Research · doi:10.1186/s40364-026-00957-5 · Cited by 7
Wang, Z., Feng, S., Yao, X., Zhao, R., Li, Y., Zheng, M., Li, Z., & Wang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1620895 · Cited by 6
Viability of diffuse large B-cell lymphoma cells is regulated by kynurenine 3-monooxygenase activity
Morita, N., Hoshi, M., Hara, T., Ninomiya, S., Enoki, T., Yoneda, M., Tsurumi, H., & Saito, K. (2021) · Oncology Letters · doi:10.3892/ol.2021.13051 · Cited by 6
Microbiota-derived metabolites in cancer: Dual roles in pathogenesis and opportunities for therapy
Rajak, M., Dash, D., & Koiri, R. K. (2025) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2025.100245 · Cited by 9
Xiang, Y., Zhang, L., Ye, J., Chen, Y., Ren, Q., Su, B., Xu, X., & Zhang, Q. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.03.011 · Cited by 8
Structural Basis of Selective Human Indoleamine‐2,3‐dioxygenase 1 (hIDO1) Inhibition
Kassab, S. E., & Mowafy, S. (2021) · ChemMedChem · doi:10.1002/cmdc.202100253 · Cited by 5
Yamamoto, N., Satouchi, M., Doi, T., Fujiwara, Y., Yanagitani, N., Kawa, Y., Yoh, K., Leopold, L. H., Munteanu, M. C., Sawada, T., et al. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01422-6 · Cited by 5
Self-citationMirabile, A., Rivoltini, L., Daveri, E., Vernieri, C., Mele, R., Porcu, L., Lazzari, C., Bulotta, A., Viganò, M. G., Cascinu, S., et al. (2020) · Cancers · doi:10.3390/cancers12051153 · Cited by 5
Jin, F., Hu, Q., Fei, H., Lv, H., Wang, S., Gui, B., Zhang, J., Tu, W., Zhang, Y., Zhang, L. J., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00443 · Cited by 5
Immunotherapy in gastrointestinal stromal tumors: Current landscape and future horizons
Papadakos, S. P., Argyrou, A., Karniadakis, I., Vogli, S., & Theocharis, S. E. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i6.104314 · Cited by 7
Hu, H., Li, M., Wu, D., Li, Z., Miao, R., Liu, Y., & Gong, P. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.048 · Cited by 4
Foglia, B., Nurcis, J., Signorini, M., & Cannito, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1823145 · Cited by 3
Abdesheikhi, J., Sedghy, F., Mahmoodi, M., Fallah, H., & Ranjkesh, M. (2023) · Iranian Biomedical Journal · doi:10.52547/ibj.3811 · Cited by 4
Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab
von Bubnoff, D., Schmitt, C., Goldinger, S. M., Schadendorf, D., Kähler, K. C., Hafner, C. M., Kramer, N., Fröhlich, W., Dummer, R., Berking, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321937 · Cited by 3
Chakraborty, B., Agarwal, S., Kori, S. K., Das, R., Kashaw, V., Iyer, A. K., & Kashaw, S. K. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230505165031 · Cited by 3
Spatiotemporally Controlled T‐Cell Combination Therapy for Solid Tumor
Hao, M., Zhou, Y., Chen, S., Jin, Y., Li, X., Xue, L., Shen, M., Li, W., & Zhang, C. (2024) · Advanced Science · doi:10.1002/advs.202401100 · Cited by 2
Indoleamine 2,3-Dioxygenase (IDO) and Cancerous Cells
Safdarian, A. R., Farhangnia, P., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_72-1 · Cited by 2
Coluccia, M., Secci, D., & Guglielmi, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823974-2.00024-3 · Cited by 2
Wang, Z., Li, W., & Lu, J. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00281-8 · Cited by 2
Inuki, S., Ohno, H., Yamaguchi, A., Ohta, K., Oishi, S., & Asai, A. (2021) · Heterocycles · doi:10.3987/com-20-s(k)17 · Cited by 2
Detection of indoleamine 2,3-dioxygenase 1-expressing cells in canine normal and tumor tissues
Ikeda, N., Kato, D., Tsuboi, M., Yoshitake, R., Eto, S., Yoshimoto, S., Shinada, M., Kamoto, S., Hashimoto, Y., TAKAHASHI, Y., et al. (2021) · Journal of Veterinary Medical Science · doi:10.1292/jvms.21-0217 · Cited by 2
Targeting Leukemia Stem Cells and the Immunological Bone Marrow Microenvironment
Maccalli, C., Tasian, S. K., & Rutella, S. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-16624-3_7 · Cited by 2
Caution in the age of optimism; a salient lesson in advanced melanoma
Roberts, H. N., & Haydon, A. M. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.125 · Cited by 2
Valuable insights from the epacadostat plus pembrolizumab clinical trials in solid cancers
Mitchell, T. C. (2024) · BMC Cancer · doi:10.1186/s12885-024-12432-1 · Cited by 2
Zhang, C., Yang, A., Lin, H., Li, Z., & Lü, W. (2026) · Journal of Functional Biomaterials · doi:10.3390/jfb17020094 · Cited by 1
Indoleamine 2,3-dioxygenase 1 expression predicts cholangiocarcinoma patient survival
Naeklang, M., Dokduang, H., Prajumwongs, P., Klanrit, P., Wangwiwatsin, A., Namwat, N., Titapun, A., Sa-Ngiamwibool, P., & Loilome, W. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105042 · Cited by 1
Zhang, Y., Ouyang, J., Yan, Q., Ge, J., Wu, P., Wang, D., Li, L., Zhang, J., Zhong, Y., Yang, L., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.04.055 · Cited by 1
Bublevič, J. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.12.002325
Precision oncology: myth or reality?
Slavyanskaya, T. A., & Salnikova, S. V. (2019) · Bulletin of Russian State Medical University · doi:10.24075/vrgmu.2019.018 · Cited by 1
Li, H., Liu, J.-W., Wang, J., Li, Z., Yu, J., Huang, X. P., Wan, B., Meng, X., & Zhang, X. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15120372 · Cited by 1
Espíndola, L. M. D., Salhab, R. M., dos Anjos, C. H., Garicochea, B., & Munhoz, R. R. (2017) · Clinical skin cancer · doi:10.1016/j.clsc.2017.06.003 · Cited by 1
Prendergast, G. C., Malachowski, W. J., Mondal, A., Scherle, P., & Muller, A. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_17 · Cited by 1
Self-citationCheckpoint inhibition in the fight against cancer: NK cells have some to say in it
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., & Gonzalez, S. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00013-8 · Cited by 1
Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Scholtens, D. M., Savoor, R., Zhang, B., Wu, J. D., Horbinski, C., Lukas, R. V., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1548242 · Cited by 1
Immune Checkpoint Combinations with Inflammatory Pathway Modulators
DeVito, N. C., Morse, M. A., Hanks, B. A., & Clarke, J. M. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_8
Zhang, S. V., Tan, M., Navarro, F. C. P., Northcott, J. M., Ma, S., Nelson, C., Bhave, D. P., Bentley, L. G., Chinnappa, M., Norton, D., et al. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0029
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020
Ascierto, P. A., Brody, J., Butterfield, L. H., Finn, O. J., Goldberg, J., Perrone, F., Sullivan, R. J., Fox, B. A., Hwu, P., & Puzanov, I. J. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02811-8
The indoleamine 2,3 dioxygenase pathway drives intratumoral B cell maintenancePreprint
Johnson, B. A., Aragaki, A. K., Williams, D. M., Rogers, O. C., Mountain, J., Luo, L., Zhang, W., Xian, L., Feng, M., Chia, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.25.456776
Heinzerling, L., Hartmann, A., & Hund, M. (2019) · Springer eBooks · doi:10.1007/978-3-662-58012-7_2
Daniels, G. A. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_11
Buesking, A. W., Mayes, P. A., & Combs, A. P. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc272
Immunotherapy in the Treatment of Advanced Colorectal Cancer
Raman, P., Botrus, G., & Bekaii‐Saab, T. (2022) · Cancer immunotherapy · doi:10.1007/13905_2021_12
Lee, S. Y., & Bhatia, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00002-0
(2019) · Вестник Российского государственного медицинского университета · doi:10.24075/vrgmu.2019-02
(2019) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2019-02
Immune Cell Metabolites as Fuel for Cancer Cells
Aggarwal, V., Rathod, S., Vashishth, K., & Upadhyay, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_6
THE RISE, FALL, AND FUTURE PROMISE OF IDO1 INHIBITORS FOR IMMUNO-ONCOLOGY
Cherney, E. C., Williams, D. K., Zhang, L., & Nara, S. J. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch18
OX40 and CD40 Agonists for the Treatment of Lung Cancer
Verma, N., Thapa, K., Kanojia, N., Sood, P., Kumar, J., Thakur, N., & Dua, K. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_10
IDO and TGF-β Inhibitors for the Treatment of Lung Cancer
Devadoss, T., Yeole, K. R., Rajesh, R. B., & Sambhaji, B. C. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_9
Immunotherapy Combinations and Dual Checkpoint Blockade
Kearney, M., Wooster, M. E., & Kalinsky, K. M. (2024) · Cancer immunotherapy · doi:10.1007/13905_2024_42
Zhao, L., Huang, C., Zheng, R., Zhou, H., Chen, G., Ye, Y., Miao, Y., & Li, S. (2025) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70024
Indoleamine 2,3-Dioxygenase (IDO) and Cancerous Cells
Safdarian, A. R., Farhangnia, P., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_72
李, 文. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123452
Cho, B. C., Braña, I., Cirauqui, B., Aksoy, S., Couture, F., Hong, R.-L., Miller, W. H., Chaves-Conde, M., Teixeira, M., Leopold, L. H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26378014
Self-citationNecchi, A., Van der Heijden, M. S., Trukhin, D. V., Peer, A., Gurney, H., Alekseev, B. Y., Parnis, F. X., Leibowitz, R., De Santis, M., Grivas, P. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26377974
Self-citationTokito, T., Kolesnik, O., Sørensen, J., Artac, M., Quintela, M. L., Lee, J.-S., Hussein, M., Pless, M., Paz-Ares, L., Leopold, L. H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26378046
Self-citationÇiçin, İ., Plimack, E. R., Gurney, H., Leibowitz, R., Alekseev, B. Y., Parnis, F. X., Peer, A., Necchi, A., Joaquim Bellmunt, B., Nishiyama, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26378124
Self-citationÇiçin, İ., Plimack, E. R., Gurney, H., Leibowitz, R., Alekseev, B. Y., Parnis, F. X., Peer, A., Necchi, A., Joaquim Bellmunt, B., Nishiyama, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26377987
Self-citationBoyer, M. J., Hui, R., Urban, D., Clingan, P., Su, W., Devaux, C., Gadgeel, S., Garassino, M., Leopold, L. H., Daniel, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26377977
Self-citationLiu, J.-S., Cai, Y.-X., He, Y., Xu, J., Tian, S.-F., & Li, Z. (2024) · Figshare · doi:10.6084/m9.figshare.25059411
Necchi, A., Van der Heijden, M. S., Trukhin, D. V., Peer, A., Gurney, H., Alekseev, B. Y., Parnis, F. X., Leibowitz, R., De Santis, M., Grivas, P. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26378125
Self-citation
Metadata
- Authors
- Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., & Gajewski, T. F.
- Affiliations
- Abramson Cancer Center (US)
- Incyte (United States) (US)
- University of Chicago (US)
- Corresponding author
- Beatty, Gregory L.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2017-07-01
- Volume
- 23
- Issue
- 13
- Pages
- 3269-3276
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5496788
- OpenAlex
- W2570766240
- Cited by
- 314
- References
- 40
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 42 · 2023: 21 · 2022: 26 · 2021: 36 · 2020: 33 · 2019: 44 · 2018: 53 · 2017: 24
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Chicago
- Abramson Cancer Center
- National Cancer Institute (K08CA138907)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- epacadostat, IDO1, IDO1 inhibitors, advanced solid tumors, kynurenine, kynurenine/tryptophan ratio, tryptophan degradation, tumor immunosuppression, radiation pneumonitis, dose-limiting toxicity, pharmacokinetics, pharmacodynamics, anticancer activity, maximum tolerated dose
- MeSH terms
- Administration, Oral, Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms, Oximes, Sulfonamides, Indoleamine-Pyrrole 2,3,-Dioxygenase, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
